HomeAI · summaries
Storia in 6 fonti
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug
Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with Lilly and Alkermes close behind.
- ·
morningstar.com
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
